This finding is reinforced by our analysis, indicating that among CRSwNP cases predominantly characterized by type 2 inflammation, monoclonal antibodies targeting IL-4Rα, which block the IL-4/IL-13 signaling pathway, are the most effective. This evidence concerns the gene IL4 and chronic rhinosinusitis with nasal polyps.